Rituximab treatment of post-COVID-19 development of acute-onset chronic inflammatory demyelinating polyneuropathy

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F22%3AE0109740" target="_blank" >RIV/00843989:_____/22:E0109740 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/22:A2302JLC
Result on the web
<a href="https://www.csnn.eu/casopisy/ceska-slovenska-neurologie/2022-4-7/post-covid-19-vyvoj-chronicke-zanetlive-demyelinizacni-polyneuropatie-s-akutnim-zacatkem-lecene-rituximabem-131783/download?hl=cs" target="_blank" >https://www.csnn.eu/casopisy/ceska-slovenska-neurologie/2022-4-7/post-covid-19-vyvoj-chronicke-zanetlive-demyelinizacni-polyneuropatie-s-akutnim-zacatkem-lecene-rituximabem-131783/download?hl=cs</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.48095/cccsnn2022336" target="_blank" >10.48095/cccsnn2022336</a>

Result language
angličtina
Original language name
Rituximab treatment of post-COVID-19 development of acute-onset chronic inflammatory demyelinating polyneuropathy
Original language description
A case report of a patient with post-COVID-19 development of acute-onset chronic inflammatory demyelinating polyneuropathy.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30210 - Clinical neurology

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Result description